PharmaVOICE - 
February 2016
Purchase Issue

PV0216_Cover

In Every Issue
Letter from the Editor
Celebrating 15 Years PharmaVOICE has embarked upon a year of [...]
By

Taren Grom, Editor

UpFront
Industry at Large Astellas Partners with Aspiritech to Advance Opportunities [...]
By

PharmaVOICE Staff

Innovator’s Corner
Researching Gene Therapies for Rare Diseases Karen Aiach, Founder and [...]
By

Karen Aiach, Founder and CE, Lysogene

mHealth
Novartis and Qualcomm’s Inhaler Device Helps Manage COPD Trendwatch: Apps [...]
By

PharmaVOICE Staff

Pharma Trax
Biopharma Sales Operations Stabilizing Trending now: Growth in sales operations [...]
By

PharmaVOICE Staff

What’s New
Baxalta Opens Global Innovation Center Trending now:  Baxalta joins growing [...]
By

PharmaVOICE Staff

Tools of the Trade
Veeva Systems and UL EduNeering Partner to Deliver Integrated Learning [...]
By

PharmaVOICE Staff

The Calendar
Coming Attractions The Pennsylvania BIO 2016 Annual Dinner and Awards [...]
By

PharmaVOICE Staff

Talent Pool
Pharma pool Paris Panayiotopoulos Ariad Names President and CEO Paris [...]
By

PharmaVOICE Staff

Last Word
Patient Advocacy in Rare Diseases Michelle Berg, VP of Patient [...]
By

Michelle Berg, VP of Patient Advocacy, Abeona Therapeutics

On The Cover

Reflections and Predictions
The world today is much different from when PharmaVOICE began publishing 15 years ago. In the United States, George W. Bush had just taken office, replacing Bill Clinton. Today, Jeb Bush and Hillary Clinton are running for president. Okay, so while some of the names in politics remain the same, the country and the world [...]
By

Taren Grom, Editor

Features

Global Launches
Most of today’s new therapy launches are global, but the strategy behind those launches has changed significantly, due to the advent of more specialty drugs targeting smaller populations, and the impact of the shift in decision making from physician to payer. The industry can no longer rely on physician promotion only for a successful global [...]
By

Robin Robinson

Advertising to Segments of the Customer Base
For many marketers today, audience segmentation is becoming a key strategic activity when conducting audience analysis. At the most basic level, audience segmentation is the process of dividing a large group of people into homogeneous subgroups — or segments — based upon those who have similar needs or on defined criterion such as product usage, [...]
By

Taren Grom, Editor

The Coming Antibiotic Crisis
For the last 70 years, antibiotics have greatly reduced illness and death from infectious diseases. But these drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. In the past 25 years, there has been a [...]
By

Denise Myshko

Patients and Patient Organizations Power Rare Disease Therapies
For most of the pharmaceutical industry, the focus on patient centricity is a relatively new phenomenon, and the industry continues to shift its focus to include patients as stakeholders when planning its marketing strategies, clinical trials, and R&D strategies. However, for the rare disease sector, the patient has always been front and center, championing for [...]
By

Robin Robinson

Mental Illness: An Underserved Area
Advances in brain science and the understanding of mental health disorders have led to the approval of new medicines, but mental health disorders still take a huge toll on Americans. The National Institute of Mental Health (NIMH) estimates that one in four American adults — 61.5 million people — have been diagnosed with a mental [...]
By

Denise Myshko

Alzheimer’s Research Update
Alzheimer’s is at the forefront of brain research; 90% of what we know about Alzheimer’s has been discovered in the last 15 years. But while research has discovered much about this devastating disease, there is still much we don’t know. Alzheimer’s is one of the most complex diseases researchers have ever studied. There are many [...]
By

Denise Myshko

Quiet Achiever: Japan Puts Focus On Innovation
A s one of the world’s biggest economies and a well-established pharmaceutical powerhouse, Japan has for many years been a difficult market for foreign companies to enter independently. Increasingly, however, the Japanese market is opening to international companies. “In the past companies were essentially entering the market through joint ventures with local Japanese pharmaceutical companies; now [...]
By

Kim Ribbink

SHOWCASE FEATURE: Outsourcing: Strategic Partnerships
After years of paying lip service to the need for truly strategic partnerships between sponsors and CROs as a way to increase efficiencies, improve timelines to market, and reduce costs, the time may be right for both parties. According to Nice Insights’ most recent survey 2016 CRO Buying Trends, 77% of respondents reported that it [...]
By

Taren Grom

Countdown to Launch: Strategies For Efficiency, Acceleration and Performance
As new drug launches proliferate in the increasingly complex specialty therapeutic space, biopharma is finding that success is often pre-determined by actions that take place very early in the development and commercialization cycle. In fact, the earlier companies start thinking through their launch strategy, the better. In particular, emerging companies that are pouring in millions [...]
By

Dean Giovanniello, Principal, Advisory Services and Steve Devrieze, VP, Head of Emerging Biopharma and Technologies, U.S. Commercial, Quintiles

FEEDBACK